On May 4, the FDA approved andexanet alpha (AndexXa, Portola Pharmaceuticsls) as the first and only reversal agent for direct anti-Xa DOACs rivaroxaban (Xarelto), and apixaban (Eliquis) overdose. Tap or click MD Magazine for details. Also see the ANEXXA-A report in Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med. 2015 17:2413–24. Thanks to Dave McGlasson for the heads-up.